Song Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Song Jin has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Chang‐Ye Zou
Department of Orthopedic Surgery, The First Affiliated Hospital, Sun Yat‐Sen University, Guangzhou, China
1 shared publication- Gang Huang
Department of Organ Transplantation, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China
1 shared publication Jia‐Guo Zhou
Department of Pharmacology, Zhongshan Medical College, Sun Yat‐Sen University, Guangzhou, China
1 shared publication- Jie Jin
Department of Urology, Peking University First Hospital, Beijing, China
1 shared publication Jie Liu
Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, Beijing, China
1 shared publication- Jie Ming
Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 30 October 2025
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 26 (1) , 1-17
Imidacloprid contributes to bladder cancer progression: preliminary evidence based on network toxicology, machine learning and molecular docking
Imidacloprid (IMI) has been widely used in agriculture and is increasingly infiltrating urban environments. This study aimed to investigate the role of IMI in the development of bladder cancer (BCa) and its potential molecular mechanisms. IMI-related genes were obtained from the CTD database. Differentially expressed IMI-related genes (DEIRGs) in BCa were identified through differential analysis of RNA-seq data from TCGA database, followed by KEGG and GO enrichment analyses to explore their biological functions. Ten machine learning algorithms and their combinations were applied to construct prognostic models based on DEIRGs in TCGA cohort, with external validation in two independent cohorts (GSE13507 and GSE31684). Multivariate Cox regression analyses were further used to develop a DEIRG-based risk score model for patient risk stratification. Drug sensitivity analyses were performed using the pRRophetic R package. Molecular docking was conducted using the CB-Dock2 tool. Colony formation, wound healing, and transwell invasion assays were used to evaluate the biological behaviors of BCa cells. Real-Time quantitative Polymerase Chain Reaction (RT-qPCR) and western blot analyses were performed to evaluate the expression levels of key genes. A total of 138 DEIRGs were identified, which were enriched in pathways including insulin resistance, chemical carcinogenesis, cAMP, FoxO, and AMPK signaling. Machine learning models based on these genes demonstrated robust prognostic performance across all three cohorts. Five key genes (SREBF1, PRELP, TGFBI, TNFAIP2 and TACR3) were further selected via multivariate Cox regression, and patients in the high-risk group exhibited significantly worse prognosis than those in the low-risk group (all p < 0.05). A nomogram integrating the risk score and clinicopathological features enabled individualized survival prediction. The high-risk group was more sensitive to drugs such as Rizavasertib, Saracatinib, and Motesanib, whereas the low-risk group was more sensitive to drugs such as Rucaparib, Veliparib, and Axitinib. Molecular docking demonstrated strong binding affinity of IMI to these five target proteins. In vitro experiments further showed that IMI at occupational exposure concentrations (10 ng/mL) in urine significantly promoted the proliferation, migration, and invasion of BCa cells. RT-qPCR and western blot analyses confirmed that IMI exposure upregulated the expression of SREBF1, PERLP, and TGFBI, and downregulated the expression of TNFAIP2, while having no significant effect on TACR3 expression. This study suggests that IMI may promote BCa development and sheds light on potential molecular mechanisms. Moreover, a DEIRG-based risk stratification model may facilitate personalized treatment decisions for BCa patients.
- 30 October 2025
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 26 (1) , 1-17
Open AccessImidacloprid contributes to bladder cancer progression: preliminary evidence based on network toxicology, machine learning and molecular docking
Imidacloprid (IMI) has been widely used in agriculture and is increasingly infiltrating urban environments. This study aimed to investigate the role of IMI in the development of bladder cancer (BCa) and its potential molecular mechanisms. IMI-related genes were obtained from the CTD database. Differentially expressed IMI-related genes (DEIRGs) in BCa were identified through differential analysis of RNA-seq data from TCGA database, followed by KEGG and GO enrichment analyses to explore their biological functions. Ten machine learning algorithms and their combinations were applied to construct prognostic models based on DEIRGs in TCGA cohort, with external validation in two independent cohorts (GSE13507 and GSE31684). Multivariate Cox regression analyses were further used to develop a DEIRG-based risk score model for patient risk stratification. Drug sensitivity analyses were performed using the pRRophetic R package. Molecular docking was conducted using the CB-Dock2 tool. Colony formation, wound healing, and transwell invasion assays were used to evaluate the biological behaviors of BCa cells. Real-Time quantitative Polymerase Chain Reaction (RT-qPCR) and western blot analyses were performed to evaluate the expression levels of key genes. A total of 138 DEIRGs were identified, which were enriched in pathways including insulin resistance, chemical carcinogenesis, cAMP, FoxO, and AMPK signaling. Machine learning models based on these genes demonstrated robust prognostic performance across all three cohorts. Five key genes (SREBF1, PRELP, TGFBI, TNFAIP2 and TACR3) were further selected via multivariate Cox regression, and patients in the high-risk group exhibited significantly worse prognosis than those in the low-risk group (all p < 0.05). A nomogram integrating the risk score and clinicopathological features enabled individualized survival prediction. The high-risk group was more sensitive to drugs such as Rizavasertib, Saracatinib, and Motesanib, whereas the low-risk group was more sensitive to drugs such as Rucaparib, Veliparib, and Axitinib. Molecular docking demonstrated strong binding affinity of IMI to these five target proteins. In vitro experiments further showed that IMI at occupational exposure concentrations (10 ng/mL) in urine significantly promoted the proliferation, migration, and invasion of BCa cells. RT-qPCR and western blot analyses confirmed that IMI exposure upregulated the expression of SREBF1, PERLP, and TGFBI, and downregulated the expression of TNFAIP2, while having no significant effect on TACR3 expression. This study suggests that IMI may promote BCa development and sheds light on potential molecular mechanisms. Moreover, a DEIRG-based risk stratification model may facilitate personalized treatment decisions for BCa patients.
- Open Access
- 8 April 2019
- Published by Wiley in The Prostate
- Vol. 79 (8) , 909-919
Activation of cGMP/PKG/p65 signaling associated with PDE5‐Is downregulates CCL5 secretion by CD8+ T cells in benign prostatic hyperplasia
Background: Benign prostatic hyperplasia (BPH) is the most common urological disease in elderly men, but the underlying pathophysiological mechanisms are complex and not fully understood. Phosphodiesterase type 5 inhibitors (PDE5‐Is) used to treat BPH could upregulate the cyclic guanosine monophosphate (cGMP)‐dependent protein kinase G (PKG) signaling, which was shown to blunt inflammation in the prostate. Our previous findings indicate that CD8+ T cells promote the proliferation of BPH epithelial cells (BECs) in low androgen conditions through secretion of CCL5; however, the role of the cGMP/PKG pathway in the process is unclear.Methods: Paraffin‐embedded tissues were used for expression quantity of CD8+ T cells, CCL5, cyclin D1, and PDE5 protein by immunohistology in prostate specimens which were/were not treated with finasteride 5 mg daily for at least 6 months before surgery. BPH‐1 cells were cocultured with or without CD8 + T cells or PDE5‐Is in low androgen conditions for 4 days. The conditioned media, BPH‐1 cells, and CD8 + T cells were harvested for the subsequent experiments. The quantitative polymerase chain reaction was used for assaying the level of messenger RNA expression of CCL5. CCL5 in the conditioned media was detected by the enzyme‐linked immunosorbent assay. The effect of PDE5‐Is on cocultured BPH‐1/CD8 + T‐cell proliferation was detected by the cell counting kit‐8. A high‐fat diet (HFD)‐induced prostatic hyperplasia rat model was used to investigate the effect of cGMP/PKG activation in CD8 + T cells in vivo.Results: CD8+ T‐cell infiltration into human BPH tissues was positively correlated with the expression of CCL5, cyclin D1, and PDE5, whereas in an HFD‐induced prostatic hyperplasia rat model, the activation of the cGMP/PKG signaling by a PDE5‐I could suppress the CD8 + T‐cell infiltration and the CCL5 and cyclin D1 expression. Furthermore, the activation of the cGMP/PKG pathway inhibited CCL5 secretion by CD8 + T cells by downregulating nuclear factor‐κB p65 phosphorylation, which reduced the growth of BPH‐1 through CCL5/STAT5/CCND1 signaling.Conclusions: Our results indicate that the upregulation of the cGMP/PKG/p65 signaling reduces CCL5 secretion in CD8 + T cells, which in turn decreases the proliferation of BECs in low androgen conditions, suggesting that the combination of 5α reductase inhibitors lowering androgen levels and PDE5‐Is may be a novel, more effective treatment for BPH patients.
- 8 April 2019
- Published by Wiley in The Prostate
- Vol. 79 (8) , 909-919
Open AccessActivation of cGMP/PKG/p65 signaling associated with PDE5‐Is downregulates CCL5 secretion by CD8+ T cells in benign prostatic hyperplasia
Background: Benign prostatic hyperplasia (BPH) is the most common urological disease in elderly men, but the underlying pathophysiological mechanisms are complex and not fully understood. Phosphodiesterase type 5 inhibitors (PDE5‐Is) used to treat BPH could upregulate the cyclic guanosine monophosphate (cGMP)‐dependent protein kinase G (PKG) signaling, which was shown to blunt inflammation in the prostate. Our previous findings indicate that CD8+ T cells promote the proliferation of BPH epithelial cells (BECs) in low androgen conditions through secretion of CCL5; however, the role of the cGMP/PKG pathway in the process is unclear.Methods: Paraffin‐embedded tissues were used for expression quantity of CD8+ T cells, CCL5, cyclin D1, and PDE5 protein by immunohistology in prostate specimens which were/were not treated with finasteride 5 mg daily for at least 6 months before surgery. BPH‐1 cells were cocultured with or without CD8 + T cells or PDE5‐Is in low androgen conditions for 4 days. The conditioned media, BPH‐1 cells, and CD8 + T cells were harvested for the subsequent experiments. The quantitative polymerase chain reaction was used for assaying the level of messenger RNA expression of CCL5. CCL5 in the conditioned media was detected by the enzyme‐linked immunosorbent assay. The effect of PDE5‐Is on cocultured BPH‐1/CD8 + T‐cell proliferation was detected by the cell counting kit‐8. A high‐fat diet (HFD)‐induced prostatic hyperplasia rat model was used to investigate the effect of cGMP/PKG activation in CD8 + T cells in vivo.Results: CD8+ T‐cell infiltration into human BPH tissues was positively correlated with the expression of CCL5, cyclin D1, and PDE5, whereas in an HFD‐induced prostatic hyperplasia rat model, the activation of the cGMP/PKG signaling by a PDE5‐I could suppress the CD8 + T‐cell infiltration and the CCL5 and cyclin D1 expression. Furthermore, the activation of the cGMP/PKG pathway inhibited CCL5 secretion by CD8 + T cells by downregulating nuclear factor‐κB p65 phosphorylation, which reduced the growth of BPH‐1 through CCL5/STAT5/CCND1 signaling.Conclusions: Our results indicate that the upregulation of the cGMP/PKG/p65 signaling reduces CCL5 secretion in CD8 + T cells, which in turn decreases the proliferation of BECs in low androgen conditions, suggesting that the combination of 5α reductase inhibitors lowering androgen levels and PDE5‐Is may be a novel, more effective treatment for BPH patients.
- Open Access
- 7 March 2007
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 1 (3) , 272-285
2‐D DIGE and MALDI‐TOF‐MS analysis of the serum proteome in human osteosarcoma
We performed 2‐D DIGE on proteins prepared from serum obtained from patients with osteosarcoma (OS) and controls, to identify differentially expressed proteins that might serve as serum biomarkers for OS prognosis. Proteins found to be differentially expressed were identified by MALDI‐TOF mass spectrometric analysis, coupled with database interrogation. We compared serum samples from four individuals with OS to four age‐ and sex‐matched healthy controls. We identified 24 protein spot‐features that were significantly increased, and 34 that were significantly decreased in serum from patients with OS relative to the controls. The MS analysis revealed 18 unique proteins that were increased, and 25 unique proteins that were decreased in OS serum samples. Western blot and ELISA analysis confirmed increased levels of amyloid‐related serum protein (SAA) in the OS serum samples. The increased expression levels of SAA were decreased after using MTX and cisplatin combination chemotherapy, and were further decreased after operation. Moreover, increased expression levels of sera SAA were seen in the relapsed patients. Our results suggested that the determination of serum SAA in OS patients might be utilized as a marker for relapse and in evaluation of the efficacy of therapy.
- 7 March 2007
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 1 (3) , 272-285
Open Access2‐D DIGE and MALDI‐TOF‐MS analysis of the serum proteome in human osteosarcoma
We performed 2‐D DIGE on proteins prepared from serum obtained from patients with osteosarcoma (OS) and controls, to identify differentially expressed proteins that might serve as serum biomarkers for OS prognosis. Proteins found to be differentially expressed were identified by MALDI‐TOF mass spectrometric analysis, coupled with database interrogation. We compared serum samples from four individuals with OS to four age‐ and sex‐matched healthy controls. We identified 24 protein spot‐features that were significantly increased, and 34 that were significantly decreased in serum from patients with OS relative to the controls. The MS analysis revealed 18 unique proteins that were increased, and 25 unique proteins that were decreased in OS serum samples. Western blot and ELISA analysis confirmed increased levels of amyloid‐related serum protein (SAA) in the OS serum samples. The increased expression levels of SAA were decreased after using MTX and cisplatin combination chemotherapy, and were further decreased after operation. Moreover, increased expression levels of sera SAA were seen in the relapsed patients. Our results suggested that the determination of serum SAA in OS patients might be utilized as a marker for relapse and in evaluation of the efficacy of therapy.